Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response

Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle. Recent advances in the identification of PARPi resistance mechanisms have yielded a better under...

Descripción completa

Detalles Bibliográficos
Autores principales: Francica, Paola, Rottenberg, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309079/
https://www.ncbi.nlm.nih.gov/pubmed/30593284
http://dx.doi.org/10.1186/s13073-018-0612-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309079/
https://www.ncbi.nlm.nih.gov/pubmed/30593284
http://dx.doi.org/10.1186/s13073-018-0612-8

Ejemplares similares